Literature DB >> 2106441

Reconstitution of H-2 class I expression by gene transfection decreases susceptibility to natural killer cells of an EL4 class I loss variant.

K Sturmhöfel1, G J Hämmerling.   

Abstract

Several reports have suggested that an inverse correlation exists between major histocompatibility complex class I expression and the susceptibility to natural killer (NK)-mediated lysis. For example, the increased class I expression induced by interferon-gamma was always accompanied by an increased resistance to NK lysis. Likewise, class I loss variants were often more NK susceptible than their normal counterparts. To investigate whether the inverse correlation between class I expression and NK susceptibility was fortuitous or whether the class I molecules were directly responsible for this effect we resorted to gene transfection studies. From the murine thymoma line EL4 and H-2Db- and Kb-negative variant S3 was selected. This variant was highly susceptible to NK lysis. S3 was found to have a defect in beta 2-microglobulin gene expression. Therefore, restoration of Db and Kb expression could be achieved by transfection with the beta 2-microglobulin gene. This resulted in a strong decrease in susceptibility to NK lysis to the level of the H-2+ parental EL4. Transfection with class II genes had no effect. Blocking of the class I molecules on the H-2+ cells with anti-H-2b F(ab')2 fragments increased the susceptibility to NK cells to the level of the H-2- variant S3. These data demonstrate that the class I molecules on the targets are directly responsible for regulation of NK susceptibility but the mechanism is not clear. Possibly the class I molecules interfere with the unknown NK target structures.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106441     DOI: 10.1002/eji.1830200125

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Histocompatibility antigens and natural killer susceptibility.

Authors:  J Peña; R Solana
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 2.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2.

Authors:  W J Storkus; R D Salter; J Alexander; F E Ward; R E Ruiz; P Cresswell; J R Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  The effect of transfected MHC class I genes on sensitivity to natural killer cells.

Authors:  M Holscher; A L Givan; C G Brooks
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

5.  ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly.

Authors:  J A Lindquist; O N Jensen; M Mann; G J Hämmerling
Journal:  EMBO J       Date:  1998-04-15       Impact factor: 11.598

6.  Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.

Authors:  M Maio; M Altomonte; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

7.  Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.

Authors:  B L Petersen; O Braendstrup
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

8.  Skin graft rejection by beta 2-microglobulin-deficient mice.

Authors:  M Zijlstra; H Auchincloss; J M Loring; C M Chase; P S Russell; R Jaenisch
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

9.  HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice.

Authors:  S Pascolo; N Bervas; J M Ure; A G Smith; F A Lemonnier; B Pérarnau
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.